// App-Quantinova.ai

1295 : Baseline characteristics from a phase 3, randomized controlled trial (COUGH‐1) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

Researchers

Presenter

  • Muccino D

Principal Investigators

  • Morice A

  • Birring SS

  • Mcgarvey L

  • Dicpinigaitis PV

  • Pavord ID

  • La Rosa C

  • Urdaneta E

  • Assaid C

  • Smith JA

Medical Centers

  • Merck & Co., Inc., Kenilworth, NJ, United States,

  • The Hull York Medical School, Cottingham, United Kingdom

  • Division of Asthma, Allergy and Lung Biology, King's College London, London, United Kingdom

  • Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom

  • Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

  • Oxford NIHR Respiratory BRC, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

  • Division of Infection, Inflammation and Respiratory Medicine, University of Manchester, Manchester, United Kingdom,

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Gefapixant

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT03449134

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved